Rocklatan Retinal Perfusion OCT Study

ConditionGlaucoma

Trial statusNot yet recruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age21+

SponsorOregon Health and Science University

About this trial

The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.

Eligibility criteria

Qualifiers

Patients with both eyes with open angle glaucoma.

Abnormal VF (glaucomatous pattern with PSD abnormal at p<0.05 or GHT outside normal limits) on most recent two clinic visits on chart review

Glaucomatous disc abnormality on chart review and confirmed on baseline disc photograph

Overall average NFL thickness > 55 μm measured by Heidelberg Spectralis OCT -Glaucoma Module Premium Edition (chart review), consistent with early glaucoma

Disqualifiers

Best corrected visual acuity worse than 20/30 on chart review of most recent clinic visit

Age < 21 years at baseline

Eye disease that could affect VF, NFL thickness, or NFLP (e.g., visually significant cataract, AMD, diabetic retinopathy, and optic neuropathy) at any study visit

OCT and OCTA scans not meeting quality criteria at baseline

Trial design

Treatments tested in this trial

Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.
Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.

Treatment groups

30 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Oregon Health and Science University

Lead sponsor

Alcon Research

Collaborator

Source ClinicalTrials.gov